vimarsana.com

Page 2 - நிறுவனம் க்கு தொகுப்பாளர் மாநாடு அழைப்பு News Today : Breaking News, Live Updates & Top Stories | Vimarsana

F-star Therapeutics, Inc : F-star Therapeutics Reports First Quarter 2021 Financial Results and Provides Corporate Update

F-star Therapeutics, Inc.: F-star Therapeutics Reports First Quarter 2021 Financial Results and Provides Corporate Update CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., May 17, 2021 (NASDAQ: FSTX), a clinical-stage biopharmaceutical company dedicated to developing next generation bispecific immunotherapies to transform the lives of patients with cancer, today announces first quarter 2021 financial results and provides a corporate update. Strengthens balance sheet with successful closing of $65 million public offering of common stock and; Received $9.2 million in net proceeds under its at-the-market equity offering program LAG-3 and PD-(L)1 co-targeting validation with LAG-3 validated in late-stage clinical trial as third checkpoint inhibitor pathway FS118 FS222 presentation at AACR on the importance of tuning both affinity and avidity for differentiation

Plug Power Completes Restatement of Previously Issued Financial Statements and Files 2020 Annual Report

Plug Power Completes Restatement of Previously Issued Financial Statements and Files 2020 Annual Report
pressreleasepoint.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pressreleasepoint.com Daily Mail and Mail on Sunday newspapers.

Great Elm Group, Inc Reports Fiscal 2021 Third Quarter Financial Results

Great Elm Group, Inc. Reports Fiscal 2021 Third Quarter Financial Results Company to Host Conference Call at 4:30 PM ET Today WALTHAM, Mass., May 14, 2021 (GLOBE NEWSWIRE) Great Elm Group, Inc. (“we,” “us,” “our,” “GEG,” or “Great Elm”) (NASDAQ: GEG), a diversified holding company, today announced financial results for its fiscal 2021 third quarter ended March 31, 2021. Fiscal 2021 Third Quarter Highlights (all comparisons versus the prior-year period unless otherwise noted) Consolidated: Consolidated net loss was $2.9 million, compared to net loss of $11.9 million Consolidated Adjusted EBITDA was $3.6 million, compared to $2.6 million Operating Companies: DME reported net loss of $5.1 million, compared to net loss of $1.4 million DME reported Adjusted EBITDA of $3.4 million, compared to $2.5 million

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.